Synonym name: Protopanaxadiol
Catalogue No.: BP0045
Cas No.: 30636-90-9
Formula: C30H52O3
Mol Weight: 460.73
Botanical Source: Panax ginseng
Purity: 30%, 40%， 90%, 95%, 99%
Analysis Method: HPLC-DAD or/and HPLC-ELSD
Identification Method: Mass, NMR
Packing: Brown vial or HDPE plastic bottle
Can be supplied from milligrams to grams, up to kilograms.
Inquire for bulk scale.
Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
60.6900
6.0000
Low
No
No
No
No
No
No
Protoginsenodiol (20(S)-Protopanaxadiol, hereinafter referred to as PPD), as one of the main active metabolites of ginsenosides, has attracted widespread attention in the field of natural product pharmacology in recent years. PPD is not only the core structural unit of various saponins in ginseng, but also, due to its diverse bioactivity and good safety performance, is considered a potential candidate for developing new therapeutic drugs. Especially in research on the prevention and treatment of metabolic diseases such as hyperglycemia, PPD has shown significant regulatory effects, involving multiple key molecular pathways and targets. This paper aims to systematically review the chemical structure and physicochemical properties of PPD, plant origin and extraction process, pharmacological activity and mechanism of action, druggability evaluation, pharmacokinetic characteristics, and clinical application prospects, providing theoretical basis and practical guidance for subsequent research and drug development.
PPD has the molecular formula C30H52O3, molecular weight 460.73, and CAS number 30636-90-9. Its chemical structure belongs to the tetracyclic triterpene compound, with a core backbone consisting of a deglycoside parent nucleus of ginseng diol-type saponins, and it has a 20(S) conformation. The PPD molecule contains three hydroxyl groups, has 3 hydrogen bond acceptors, and a polar surface area (TPSA) of 60.69 Ų, exhibiting moderate polar characteristics. Its LogP value reaches as high as 6.0, indicating strong lipid solubility that facilitates penetration of cell membranes but may affect water solubility and bioavailability.
PPD has a low blood-brain barrier penetration ability, suggesting limited distribution in the central nervous system. In terms of safety, PPD showed no hepatotoxicity, cardiotoxicity, or hERG channel inhibition, and Ames-induced mutagenic tests were also negative, indicating good safety and low mutagenic risk. These physicochemical and toxicological parameters lay the foundation for drug development for PPD.
PPD is mainly found in plants of the genus Panax in the Araliaceae family, especially in the roots of Asian ginseng (Panax ginseng C.A. Meyer) and American ginseng (Panax quinquefolius L.). Ginseng contains various saponins, and PPD is the main product of deglycosylation during its metabolism, which can also be obtained through enzymatic or microbial transformation in vivo.
Traditional extraction methods usually use alcohols (such as methanol, ethanol) as solvents, and obtain ginsenoside mixtures through hot reflux or ultrasound-assisted extraction. Subsequently, ginsenosides are converted into PPD using acid hydrolysis or enzymatic hydrolysis techniques. In recent years, the application of supercritical CO2 extraction, microwave-assisted extraction, and membrane separation technologies has improved the extraction efficiency and purity of PPD.
Purification steps commonly use silica gel column chromatography, reversed-phase high-performance liquid chromatography (RP-HPLC), and preparative liquid chromatography techniques to ensure the acquisition of high-purity PPD samples. Optimizing the extraction process not only affects yield but also relates to the accuracy of subsequent pharmacological studies and the feasibility of drug development.
PPD exhibits a wide range of pharmacological activities, covering anti-tumor, anti-inflammation, antioxidant, immunomodulatory, and metabolic regulation. Especially in studies of hyperglycemia and related metabolic diseases, PPD has shown significant effects on lowering blood sugar and improving insulin sensitivity.
Multiple in vivo and in vitro studies have shown that PPD can significantly lower blood sugar levels and improve glucose metabolism disorders. Its mechanism involves promoting pancreatic β cell function, enhancing insulin signaling, and inhibiting gluconeogenesis. PPD can also regulate glucose transporter expression, promoting tissue uptake and utilization of glucose.
Hyperglycemia is often accompanied by chronic inflammation and oxidative stress. PPD reduces tissue damage and protects islet cells and target organ function by inhibiting the release of inflammatory factors (such as TNF-α, IL-6) and enhancing antioxidant enzyme activity.
PPD also shows potential in cardiovascular protection, neuroprotection, and antitumor treatment. For example, its protective effect on myocardial cells is related to anti-apoptotic mechanisms; In the nervous system, PPD regulates neurotransmitters and protects neuronal survival.
The molecular mechanisms by which PPD regulates hyperglycemia are complex, involving multiple signaling pathways and several key targets.
PPD activates the AMPK pathway, inhibits NF-κB-mediated inflammatory responses, and regulates the PI3K/Akt signaling pathway to promote cell survival and metabolic homeostasis. Additionally, PPD affects mTOR signaling, regulates cellular autophagy and energy metabolism, and synergistically improves the pathological state of hyperglycemia.
Druggability evaluations of PPD indicate good safety and potential clinical value. With moderate molecular weight, although the high LogP may limit its water solubility and oral bioavailability, lipophilic properties facilitate cell membrane penetration.
Toxicological data indicate that PPD does not have significant hepatorenal toxicity, cardiotoxicity, or genotoxicity, and has a relatively broad safety window. Low blood-brain barrier penetration reduces the risk of central nervous system side effects.
Pharmacokinetic studies show that PPD is absorbed orally slowly, its bioavailability is limited, and it is mainly metabolized by the liver, with most metabolites being water-soluble conjugates. PPD is widely distributed in the body with a moderate half-life, making it suitable for routine administration.
To improve its pharmacokinetic properties, researchers have tried to use modern pharmaceutical technologies such as nanocarriers, liposomes, and solid dispersions to enhance PPD's solubility and bioavailability, thereby enhancing its clinical application potential.
As a natural product, PPD demonstrates unique advantages in the prevention and treatment of hyperglycemia and related metabolic diseases thanks to its multi-target and multi-pathway regulatory capabilities. Its good safety profile and diverse pharmacological activities make it a strong candidate for adjunctive treatment for diabetes and metabolic syndrome.
The key to future clinical applications lies in:
With the development of natural product pharmacology and modern drug technologies, PPD is expected to become a new model for natural drug development, ushering metabolic disease treatment into a new era of precise multi-target regulation.
Original ginseng diol (20(S)-Protopanaxadiol), as an important metabolite of ginsenosides, shows broad application prospects in the prevention and treatment of hyperglycemia and related metabolic diseases due to its unique chemical structure and diverse biological activities. Its multi-target regulatory mechanisms, good safety, and potential clinical value make it a hotspot for pharmacology research of natural products and new drug development. In the future, by combining modern pharmaceutics techniques with systems biology approaches, the mechanisms of PPD and its clinical value will be deeply explored, providing new ideas and strategies for precision treatment of metabolic diseases.
